Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.

Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ.

Int J Oncol. 2012 Jun;40(6):1900-6. doi: 10.3892/ijo.2012.1396. Epub 2012 Mar 7.

PMID:
22407457
2.

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH.

Virchows Arch. 2005 May;446(5):483-8. Epub 2005 Apr 7.

PMID:
15815931
3.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

4.

A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.

Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al.

Diagn Mol Pathol. 1995 Dec;4(4):266-73.

PMID:
8634783
5.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
6.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.

J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

PMID:
15741570
7.

Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.

Takamochi K, Oh S, Matsuoka J, Suzuki K.

Lung Cancer. 2012 Mar;75(3):313-20. doi: 10.1016/j.lungcan.2011.08.007. Epub 2011 Dec 29.

PMID:
22209037
8.

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.

Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH.

Lung Cancer. 2008 Jan;59(1):111-8. Epub 2007 Sep 29.

PMID:
17904685
9.

Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H.

Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.

10.

Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.

Sarkar FH, Li Y, Vallyathan V.

Int J Mol Med. 2001 Oct;8(4):453-9.

PMID:
11562787
11.

A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.

Sartori G, Cavazza A, Bertolini F, Longo L, Marchioni A, Costantini M, Barbieri F, Migaldi M, Rossi G.

Am J Clin Pathol. 2008 Feb;129(2):202-10. doi: 10.1309/THU13F3JRJVWLM30.

PMID:
18208799
12.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.

Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS, Iafrate AJ.

J Thorac Oncol. 2015 Aug;10(8):1156-62. doi: 10.1097/JTO.0000000000000579.

13.

Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.

Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS, Shan B, Zhang L.

Chin Med J (Engl). 2011 Jan;124(1):19-25.

PMID:
21362302
14.

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T.

Cancer Res. 2004 Dec 15;64(24):8919-23.

15.

Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.

Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G.

Am J Surg Pathol. 2008 Nov;32(11):1627-42. doi: 10.1097/PAS.0b013e31817a8a89.

PMID:
18753943
16.

Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.

Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabrò MG, De Pas T, Orlando L, Mandalà M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A.

Clin Cancer Res. 2000 Jun;6(6):2393-400.

17.

Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.

Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mallams J, Mues G.

Am J Clin Oncol. 1998 Apr;21(2):155-60.

PMID:
9537203
18.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
19.

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R.

Ann Oncol. 2014 Jan;25(1):138-42. doi: 10.1093/annonc/mdt495. Epub 2013 Dec 1.

PMID:
24297085
20.

Uncommon V599E BRAF mutations in Japanese patients with lung cancer.

Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

J Surg Res. 2006 Jun 15;133(2):203-6. Epub 2005 Dec 27.

PMID:
16376942

Supplemental Content

Support Center